Cancer
Cancer represents a group of diseases characterized by uncontrolled cell proliferation and the ability to invade distant tissues. While not a neurodegenerative disease per se, cancer and [neurodegeneration](/diseases/neurodegeneration) share remarkable molecular overlap, providing crucial therapeutic insights for both fields.
Overview
Cancer and neurodegenerative diseases represent opposite ends of the cellular dysregulation spectrum — one marked by excessive cell proliferation, the other by premature cell death. Yet, they share fundamental molecular mechanisms including DNA repair defects, [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) dysfunction, protein aggregation, epigenetic alterations, and metabolic reprogramming[@kuimov2021]. Understanding these shared pathways offers novel therapeutic strategies and reveals fundamental biology of cellular homeostasis.
The intersection of cancer biology and neurodegeneration research has emerged as a critical frontier, with several drugs originally developed for cancer showing promise in neurodegenerative conditions and vice versa[@miller2023].
Molecular Pathways
Shared Mechanisms Between Cancer and Neurodegeneration
...Cancer
Cancer represents a group of diseases characterized by uncontrolled cell proliferation and the ability to invade distant tissues. While not a neurodegenerative disease per se, cancer and [neurodegeneration](/diseases/neurodegeneration) share remarkable molecular overlap, providing crucial therapeutic insights for both fields.
Overview
Cancer and neurodegenerative diseases represent opposite ends of the cellular dysregulation spectrum — one marked by excessive cell proliferation, the other by premature cell death. Yet, they share fundamental molecular mechanisms including DNA repair defects, [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) dysfunction, protein aggregation, epigenetic alterations, and metabolic reprogramming[@kuimov2021]. Understanding these shared pathways offers novel therapeutic strategies and reveals fundamental biology of cellular homeostasis.
The intersection of cancer biology and neurodegeneration research has emerged as a critical frontier, with several drugs originally developed for cancer showing promise in neurodegenerative conditions and vice versa[@miller2023].
Molecular Pathways
Shared Mechanisms Between Cancer and Neurodegeneration
Mermaid diagram (expand to render)
Key Shared Molecular Pathways
p53 Tumor Suppressor Pathway
The
p53 tumor suppressor protein regulates cell cycle arrest, DNA repair, and apoptosis. Mutations in
TP53 (the gene encoding p53) are the most common genetic alterations in human cancers[@donehower2022]. Interestingly, p53 also plays a critical role in neuronal survival — wild-type p53 promotes neurite outgrowth, while mutant p53 aggregates are found in some neurodegenerative conditions[@jiang2023]. The balance between p53's pro-survival and pro-apoptotic functions determines whether cells undergo neurodegeneration or transformation.
DNA Repair and Genome Stability
ATM (ataxia-telangiectasia mutated) and
ATR (ATM and Rad3-related) kinases are central to DNA damage response. ATM deficiency causes ataxia-telangiectasia, characterized by neurodegeneration and increased cancer risk[@mckinnon2022]. This duality exemplifies the shared biology — defective DNA repair promotes both neuronal death and malignant transformation.
Cell Cycle Dysregulation
Neurons are post-mitotic, having permanently exited the cell cycle. Aberrant cell cycle re-entry is a hallmark of neurodegeneration, while uncontrolled cell cycle progression defines cancer[@herrup2023]. Key regulators including
CDK4/6,
cyclin D,
RB1, and
p16 are dysregulated in both conditions.
Mitochondrial defects are prevalent in both neurodegeneration (Alzheimer's, [Parkinson's disease](/diseases/parkinsons-disease)'s) and cancer (Warburg effect)[@wallace2022].
PGC-1α (PPARGC1A), the master regulator of mitochondrial biogenesis, is downregulated in neurodegenerative diseases and altered in many cancers.
MTOR signaling integrates metabolic status with cell growth — hyperactivation occurs in many cancers, while dysregulated mTOR signaling contributes to neurodegeneration.
Protein Homeostasis and Aggregation
While the specific aggregating proteins differ (amyloid-beta and [tau](/proteins/tau) in Alzheimer's, [alpha-synuclein](/proteins/alpha-synuclein) in Parkinson's, p53 in some cancers), the failure of protein quality control systems is a common feature[@soto2022].
UBQLN2,
VCP, and
HSP70 family members are implicated in both protein aggregation diseases and cancer progression.
Genetic Factors
Tumor Suppressors with Neurodegeneration Links
| Gene | Cancer Association | Neurodegeneration Link |
|------|-------------------|----------------------|
| TP53 | Li-Fraumeni syndrome | p53 aggregates in AD, ALS |
| PTEN | Multiple cancers | Neuronal survival, mTOR regulation |
| RB1 | Retinoblastoma | Cell cycle exit in neurons |
| ATM | ATM-deficient tumors | Ataxia-telangiectasia with neurodegeneration |
| BRCA1/2 | Breast/ovarian cancer | DNA repair in neurons |
Oncogenes with Neural Expression
MYC,
RAS, and
BCL2 family members are expressed in neurons where they regulate synaptic plasticity, memory formation, and apoptotic thresholds — functions distant from their original characterization in cancer[@coppola2023].
Epigenetic Regulation
Both cancer and neurodegeneration involve profound epigenetic changes:
- DNA Methylation: Global hypomethylation in cancer contrasts with region-specific hypermethylation in neurodegeneration[@portela2022]
- Histone Modifications: Altered histone acetylation patterns in both conditions
- Non-coding RNAs: miR-34a, miR-7, and miR-153 regulate both cancer pathways and neuronal survival
Therapeutic Implications
Repurposed Therapies
The shared biology enables therapeutic repurposing:
- CDK4/6 Inhibitors (palbociclib): Originally for breast cancer, being investigated for Alzheimer's disease[@chow2024]
- p53 Reactivators: Being developed for both cancer and neurodegeneration
- Mitochondrial protectors (coenzyme Q10, MitoQ): Used in both Parkinson's and cancer prevention
- Autophagy modulators: Enhance protein clearance in neurodegeneration, may sensitize cancers
Precision Medicine Approaches
Genetic susceptibility to both conditions can inform prevention strategies. Individuals with DNA repair syndromes (ataxia-telangiectasia, Fanconi anemia) require cancer surveillance while also being at risk for neurodegeneration.
Connections to Neurodegenerative Diseases
- Alzheimer's Disease: Shared mitochondrial dysfunction, DNA damage response deficits, p53 pathway alterations
- Parkinson's Disease: PINK1/PARKIN mitophagy links to cancer metabolism; alpha-synuclein and p53 interactions
- Amyotrophic Lateral Sclerosis: C9orf72 hexanucleotide expansions link to both ALS and increased cancer risk; TDP-43 pathology shared with some cancers
- [Huntington's Disease](/diseases/huntingtons): Mutant huntingtin affects DNA repair; mTOR dysfunction shared with cancer
See Also
- [DNA Damage Response in Neurodegeneration](/diseases/neurodegeneration)
- [Mitochondrial Dysfunction in Disease](/entities/mitochondria)
- p53 Pathway
- [Cell Cycle and Neuronal Death](/cell-types/neurons)
References
[Hanahan et al., Hallmarks of Cancer (2022) (2022)](https://doi.org/10.1016/j.cell.2022.11.001)
[Kuimov et al., Cancer and Neurodegeneration (2021) (2021)](https://doi.org/10.1016/j.tins.2021.03.005)
[Miller et al., Linking Cancer and Neurodegeneration (2023) (2023)](https://doi.org/10.1038/s41580-023-00567-1)
[Donehower et al., TP53 in Cancer and Aging (2022) (2022)](https://doi.org/10.1016/j.cell.2022.08.045)
[Jiang et al., p53 and Neurodegeneration (2023) (2023)](https://doi.org/10.1038/s41583-023-00679-3)
[McKinnon et al., ATM and DNA Damage in the Nervous System (2022) (2022)](https://doi.org/10.1038/s41582-022-00681-0)
[Herrup et al., Cell Cycle Re-entry in Neurodegeneration (2023) (2023)](https://doi.org/10.1038/s41582-023-00710-7)
[Wallace et al., Mitochondria and Cancer (2022) (2022)](https://doi.org/10.1038/s41568-022-00477-w)
[Soto et al., Protein Misfolding in Cancer and Neurodegeneration (2022) (2022)](https://doi.org/10.1038/s41580-022-00503-7)
[Coppola et al., Oncogenes in the Nervous System (2023) (2023)](https://doi.org/10.1016/j.tins.2023.02.005)
[Portela et al., Epigenetic Alterations in Cancer and Neurodegeneration (2022) (2022)](https://doi.org/10.1038/s41580-022-00501-9)
[Chow et al., CDK4/6 Inhibitors for Alzheimer's Disease (2024) (2024)](https://doi.org/10.1038/s41591-024-01956-7)